Alzheimer’s research has entered a new phase, with drugs now reaching clinical trials. But John Hardy, a pioneering researcher, warns that while effective treatments are on the horizon, much more is needed beyond science alone.
The amyloid theory, once controversial, now forms the basis of many promising drugs like Donanemab and Lecanemab. These can slow cognitive decline but not halt the disease entirely. The challenge lies in improving diagnosis and securing political will to invest in dementia services.
Hardy advocates using biomarkers to detect Alzheimer’s more accurately, comparing it to cholesterol tests for heart disease. He highlights that only about 60% of people diagnosed with dementia have Alzheimer's, underscoring the need for better diagnosis. Outside specialist centers, many are inaccurately labeled.
The fight against Alzheimer’s requires a multifaceted approach: more effective drugs in development, better diagnostic tools, and political commitment to invest in healthcare infrastructure. For Hardy, this battle is far from over but now has a clearer path forward.
